Celerion Gains Import License

Celerion’s clinical research operations in Belfast, Northern Ireland, have received authorization from the Medicines and Healthcare product Regulatory Agency (MHRA) to have importation of IMPs added to its manufacturing (MIA(IMP)) license. The license eliminates the need for a third party vendor to import IMPs on behalf of Celerion. According to the company, this saves time, costs, and initiates direct communication earlier with clients to expedite early-stage clinical studies.

“The addition of the import license was based on client demand and continues to demonstrate the high quality work and experience at Celerion,” said Phil Bach, vice president of Global Clinical Research at Celerion. “This import license underpins Celerion’s commitment to a global clinical strategy and reduces the lead time from study concept to first dosing. Clients also benefit from reduced costs by eliminating third party storage and transport prior to certification of the product.”